* To apply for U.S. marketing approval in the third quarter * Drug reduced severity of schizophrenia symptoms in trial * Shares rise as much as 11 pct (Adds CEO comments from conference call, background; updates share movement) April 8 (Reuters) - Alkermes Plc said it planned to seek U.S. marketing approval for its experimental drug to treat the symptoms of schizophrenia after it succeeded in a late-stage study, sending the company's shares up as much as 11...
↧